ASCO 2015

Afatinib vs Erlotinib as Second-line Therapy of Patients with Advanced Squamous Cell Carcinoma (SCC) of the Lung: Analysis from the LUX-Lung 8 Trial

Conference Correspondent - ASCO 2015 - Lung Cancer

Treatment options for patients with advanced squamous cell carcinoma (SCC) of the lung progressing after platinum-based chemotherapy are limited.a Overexpression of EGFR, ErbB, receptors and the dysregulation of their downstream pathways are implicated in SCC pathobiology. Primary analysis of the [ Read More ]

Phase 1-1B Trial of Tivantinib in Combination with Carboplatin and Pemetrexed as First-Line Treatment in Patients with Advanced Nonsquamous NSCLC or Malignant Pleural Mesothelioma

Conference Correspondent - ASCO 2015 - Lung Cancer

Tivantinib (T) is a selective non-ATP competitive oral inhibitor of MET receptor that blocks Malignant Pleural Mesothelioma (MPM) and Non Small Cell Lung Cancer (NSCLC) cell growth and migration. Zucali and coworkers1 postulated that adding T to standard first-line chemotherapy [ Read More ]